clinical trial · NCT06429787
Post Marketing Observational Study on Safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
Octapharma·—·recruiting·n = 3,574
Vitamin K-Dependent Coagulation DefectSignificant Bleeding RiskBalfaxarKcentra
brief summary
Post marketing observational study on safety of BALFAXAR vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure
started
Feb 14, 2025
primary completion
Dec 31, 2031
completion
Jun 30, 2032
last updated
Jun 4, 2025
official title
Post Marketing Observational Study on Safety of BALFAXAR® vs. KCENTRA for Reversal of Vitamin K Antagonist Induced Anticoagulation in Adults Undergoing Urgent Surgery or Invasive Procedure.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol